Skip to main content

Table 3 Observational study characteristics

From: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Study Number of patients Mean age (years) Outcome measurea CYC treatment Corticosteroid Length of follow-up (months)
Airò and colleagues [15] 13 48 FVC, 74 Intravenous, 750 mg/m2 every 3 weeks Methylprednisolone 125 mg every 3 weeks 18
    DLCO, 41    
Beretta and colleagues [14] 33 49.7 ± 10.4 DLCO, 48.8 ± 13.5 Oral, 2 mg/kg/day Prednisone 25 mg/day in the first 3 months, 5 mg for 9 months 12
Davas and colleagues, pulse CYC [12] 8 NA FVC, 86.1 Intravenous, 750 mg/m2 monthly Prednisone 10 mg/day 12
    DLCO, 60    
Davas and colleagues, oral CYC [12] 8 NA FVC, 73.2 Oral, 2 to 2.5 mg/kg/day Prednisone 10 mg/day 12
    DLCO, 59.9    
Pakas and colleagues, low-dose prednisone cohort [16] 12 48.6 ± 12.3 FVC, 54.8 Intravenous, 900 mg/kg (mean value) Prednisone low dose, <10 mg/day 12
    DLCO, 38.2    
Pakas and colleagues, high-dose prednisone cohort [16] 16 48.6 ± 12.3 FVC, 57.5 Intravenous, 900 mg/kg (mean value) Prednisone: high dose, 1 mg/kg/day for 4 weeks 12
    DLCO, 48.3    
Silver and colleagues [17] 14 46.4 ± 2.4 FVC, 51.4 ± 2.5 Oral, 1 to 2 mg/kg/day Prednisone 7.7 ± 1.2 mg/day (in 10 patients) 24
    DLCO, 54.5 ± 7.4    
Valentini and colleagues [18] 13 37.4 DLCO, 58.5 Intravenous, 500 mg/m2 on day 1, day 8 and day 15, and every 4 weeks Low dose corticosteroids (dose not specified) 12
  1. Data presented as mean ± standard deviation. AZA, azathioprine; CYC, cyclophosphamide; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; NA, not available. aPercentage predicted value at baseline.